---
title: hepatocellular carcinoma
---
# hepatocellular carcinoma

### Risk factors (globally, 3rd leading cause of cancer death, espec. in Africa & Asia)
* Cirrhosis: present in 70–90% HCC cases
* Infectious: HCV & HBV (~75%), HBV/HDV coinfection; HBV can cause HCC w/o cirrhosis
* Toxic: EtOH (⅓ cases in U.S.), tobacco, [[aflatoxin]] from Aspergillus
* Metabolic disorders: NASH, [[diabetes mellitus]], autoimmune hepatitis, hemochromatosis
### Screening (screen high-risk Pts: cirrhosis, chronic HBV)
* Ultrasonography (U/S) + AFP q 6 mos; if high-risk may alternate U/S w/ MRI
* If lesion found or increasing AFP, perform 3-phase contrast CT or MRI

### Clinical manifestations
* Exam: nonspec. c/w liver dysfxn (eg, hepatomegaly, ascites, jaundice, encephalopathy)
* Labs: coagulopathy, low albumin, elevated LFTs; r/o other etiologies of liver dysfxn

### Diagnosis
* Can diagnose w/o biopsy in high-risk Pts with 3-phase contrast CT or MRI
* Only 15% of liver masses are HCC; liver metastases from other 1° more common

### Treatment (NEJM 2019;380:1450)
[Hepatocellular Carcinoma | NEJM](https://www.nejm.org/doi/full/10.1056/NEJMra1713263)
* Localized disease (goal = cure) → resection if feasible (preferred), ablation, transarterial chemoembolization, or radiotherapy (SBRT) also options. Inadequate hepatic reserve → liver transplant if able (NEJM 1996;334:693); non-surgical local and/or systemic Rx if not.
* Systemic Rx:
    [[bevacizumab]] preferred (NEJM 2020;382:1894),
    2nd line: kinase ([[sorafenib]]) or
    PD-(L)1 inhib (Lancet 2017;389:2492 & 2018;391:1163)
[Sorafenib抗癌藥與臨床應用](https://www.taiwan-pharma.org.tw/magazine/113/019.pdf)

(HCC; qv in Heme-Onc) (Nature Reviews 2021;7:6)

* ↑ risk w/ cirrhosis of any type (leading cause of death in cirrhosis, 1–6%/y) but esp. ↑ w/ viral (Hep B/C~3–8%/y), concomitant EtOH use, obesity related NASH, HFE or diabetes

* Clinical: asx vs. hepatic decompensation (eg, ascites, HE), PVT w/ tumor thrombus

* Dx: screen Pts w/ cirrhosis q6mo w/ U/S ± AFP; alternative is dual-phase CT/MRI

* Rx: see “HCC” in Heme-Onc
